Moderna: Phase III study begins for Covid-19 drug

(CercleFinance.com) - Moderna has announces the start of its Phase III Cove study for its investigational Covid-19 vaccine (mRNA-1273), a study conducted in collaboration with the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA).


This randomised, placebo-controlled trial is expected to include approximately 30,000 participants in the US, who will receive a 100 µg dose, with the primary objective of preventing symptomatic Covid-19 disease.

In addition, at the weekend the laboratory mentioned an extension of the agreement with BARDA, for an additional commitment of up to 472 million dollars to support clinical development, including this Phase III study.


Copyright (c) 2020 CercleFinance.com. All rights reserved.